CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 6 enrolled
Drug / intervention
Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VGbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01390064
NCT01390064Phase 1Completed
CompareCT.gov

Phase 1 Safety Study of a Carbohydrate Mimotope Based Vaccine With MONTANIDE ISA 51 VG Adjuvant

University of Arkansas·interventional·Posted Jul 8, 2011·Updated Aug 20, 2019

In Brief

A Phase 1 clinical trial evaluating Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG for Stage IV Breast Cancer. Completed, enrolled 6 participants across 1 site.

Detailed Summary

Objective - Determine the safety and tolerability of a peptide mimotope-based vaccine upon immunization of breast cancer subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStage IV Breast Cancer
CountriesUnited States
CollaboratorsUnited States Department of Defense

Timeline

Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 8, 2011
Enrollment StartJul 1, 2011
Primary CompletionJul 1, 2018
Study CompletionJul 1, 2019
TodayJul 2, 2026
Enrollment to primary: 7 yearsPosted 15.0 years ago

Interventions

Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VGbiological

All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule